Composition
Inj 420mg/14ml: Pertuzumab 30mg/ml solution for infusion single use vial
Indications & Dosage
Treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel, in patients who have not received previous anti-HER2 therapy or chemotherapy: BY IV INF: Adults: Initial dose is 840mg IV INF over 60 min, followed by 420 mg IV INF over 30-60 min every 3 weeks.
Administration
Do not administer as an IV push or bolus only IV infusion initial doses over 60 min. Resuscitation facilities should be available.
Precautions
Cardiavascular disease, conditions that could impair left ventricular function, history of congestive heart failure, impaired left ventricular function, prior anthracycline exposure, radiotherapy to the chest area, recent myocardial infarction, serious cardiac arrhythmia, uncontrolled hypertension
Interactions
Anthracyclines, cyclophosphamide.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding
Side Effects
Alopecia, anaemia, arthralgia, chills, constipation, cough, decreased appetite, diarrhoea, dizziness, dry skin, dyspepsia, dyspnoea, febrile, neutropenia, headache, increased lacrimation, insomnia, left ventricular dysfunction, leucopenia, malaise, myalgia, nasopharyngitis, oedema, pain, paronychia, peripheral neuropathy, pleural effusion, pruritus, pyrexia, rash, severe hypersensitivity reactions, taste disturbance, nausea, oral mucositis, vomiting, upper respiratory-tract infection. Rare: Interstitial lung disease, bone-marrow suppression, extravasation, hyperuricaemia, thromboembolism, tumour lysis syndrome